Th1-polarizing capacity of clinical-grade dendritic cells is triggered by ribomunyl but is compromised by PGE2: The importance of maturation cocktails

Journal of Immunotherapy

Volumn 28, Issue 5, 2005, Pages 480-487

  Jongmans, Wim ^a   Tiemessen, Dorien M ^a   Van Vlodrop, Iris J H ^a   Mulders, Peter F A ^a   Oosterwijk, Egbert ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Dendritic cell; IL 10; IL 12; Maturation; Prostaglandin E2; Regulatory T cell

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 5; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROSTAGLANDIN E2; RIBOMUNYL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CANCER IMMUNOTHERAPY; CELL MATURATION; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL;

EID: 24144495503     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000171290.78495.66     Document Type: Article

References (23)

1. Steinman RM. The dendritic cells system and its role in immunogenecity. Ann Rev Immun. 1991;9:271-296.
2. Freudenthal PS, Steinman RM. The distinct surface of human blood dendritic cells, as observed after an improved isolation method. Proc Natl Acad Sci USA. 1990;87:7698-7702.
3. Romani N, Gruner S, Brang D, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med. 1994;180:83-93.
4. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994;179:1109-1118.
5. Sallusto F, Cella M, Danieli C, et al. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med. 1995;182:389-400.
6. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity. 2003;19:641-644.
7. Wang RF. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol. 2001;22:269-276.
8. Bender A, Sapp M, Schuler G, et al. Improved methods for the generation of dendritic cells from nonproliferative progenitors in human blood. J Immunol Methods. 1996;196:121-135.
9. Romani N, Reider D, Heuer M, et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods. 1996;196:137-151.
10. Jonuleit H, Kuhn U, Muller G, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol. 1997;27:3135-3142.
11. Rieser C, Böck G, Klocker H, et al. Prostaglandin E2 and tumor necrosis factor a cooperate to activate human dendritic cells: synergistic activation of interleukin 12 production. J Exp Med. 1997;186:1603-1608.
12. Kalinski P, Vieira PL, Schuitemaker JH, et al. Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood. 2001;97:3466-3469.
13. Clot J. Pharmacology of ribosomal immunotherapy. Drugs. 1997;54 (suppl 1):33-36.
14. Alexopoulou L, Holt AC, Medzhitov R, et al. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413:732-738.
15. Oosterwijk-Wakka JC, Tiemessen TM, Bleumer I, et al. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase I study. J Immunother. 2002;25:500-508.
16. Kapsenberg ML. Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol. 2003;3:984-993.
17. Figdor CG, de Vries IJ, Lesterhuis WJ, et al. Dendritic cell immunotherapy: mapping the way. Nat Med. 2004;10:475-480.
18. de Vries IJ, Lesterhuis WJ, Scharenborg NM, et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res. 2003;9:5091-5100.
19. Boccaccio C, Jacod S, Kaiser A, et al. Identification of a clinical-grade maturation factor for dendritic cells. J Immunother. 2002;25:88-96.
20. Vieira PL, de Jong EC, Wierenga EA, et al. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol. 2000;164:4507-4512.
21. Wesa AK, Galy A. IL-1 beta induces dendritic cells to produce 1L-12. Int Immunol. 2001;13:1053-1061.
22. Spisek R, Bretaudeau L, Barbieux I, et al. Standardized generation of fully mature p70 IL-12 secreting monocyte-derived dendritic cells for clinical use. Cancer Immunol Immunother. 2001;50:417-427.
23. Kaiser A, Bercovici N, Abastado JP. et al. Naive CD8+ T cell recruitment and proliferation are dependent on stage of dendritic cell maturation. Eur J Immunol. 2003;33:162-171.